Insmed CEO on what’s next for company after FDA greenlights lung disease drug

1:31   Insmed Employee Spotlight: David Cipolla 5:02   Latest read on rare disease gene therapy from Insmed CEO Will Lewis 1:42   Insmed Employee Spotlight: Kush Patel 5:25   Insmed: How We Approach Gene Therapy 1:31   A Day in the Life at Insmed – Samuel, Therapeutic Specialist 8:44   Insmed Aktie Analyse 2026: Durchbruch bei Brinsupri & Arikayce – Jetzt Kaufen? 1:50   Insmed Employee Spotlight: Claire Godbersen-Palmer 1:31   Insmed: We’re in. For whatever challenge comes next. 8:09   Insmed (INSM) stock: RISKY SETUP — 67% revenue growth 5:23   Insmed CEO Will Lewis talks its rare disease drug pipeline 11:20   Der 1-Milliarden-Mic-Drop! 🎤 Warum INSMED (INSM) jetzt explodiert 💥 5:16   Insmed CEO on lung disease treatment and path forward 4:24   Insmed 2026 Second Quarter Performance and Investor Presentation (INSM)